Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine.
about
Ongoing challenges in the management of malariaCoartem: the journey to the clinicThe clinical efficacy of artemether/lumefantrine (Coartem)Antimalarial drug resistanceEffect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South AfricaA randomized trial of artemether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand.Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient dataClinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient dataPharmacokinetic and pharmacodynamic considerations in antimalarial dose optimizationThe influence of pregnancy on the pharmacokinetic properties of artemisinin combination therapy (ACT): a systematic reviewA comparison of oral artesunate and artemether antimalarial bioactivities in acute falciparum malariaResidual antimalarials in malaria patients from Tanzania--implications on drug efficacy assessment and spread of parasite resistanceA randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancyHigh adherence to antimalarials and antibiotics under integrated community case management of illness in children less than five years in eastern UgandaEffective coverage and systems effectiveness for malaria case management in sub-Saharan African countriesA microarray-based system for the simultaneous analysis of single nucleotide polymorphisms in human genes involved in the metabolism of anti-malarial drugs.Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.Age, Weight, and CYP2D6 Genotype Are Major Determinants of Primaquine Pharmacokinetics in African Children.Update on the efficacy, effectiveness and safety of artemether-lumefantrine combination therapy for treatment of uncomplicated malaria.Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy.Treatment with coartem (artemether-lumefantrine) in Papua New GuineaAdherence to artemether-lumefantrine drug combination: a rural community experience six years after change of malaria treatment policy in Tanzania.Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria.Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria.Population pharmacokinetics and clinical response for artemether-lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Tanzania.Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjectsPharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrineArtemether bioavailability after oral or intramuscular administration in uncomplicated falciparum malariaArtemether-lumefantrine: an option for malaria.Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania.Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz.Effectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective studySupervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda.Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malariaThe effect of mobile phone text-message reminders on Kenyan health workers' adherence to malaria treatment guidelines: a cluster randomised trial.A small amount of fat does not affect piperaquine exposure in patients with malaria.Randomized trials of artemisinin-piperaquine, dihydroartemisinin-piperaquine phosphate and artemether-lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia-Thailand border areaPresumptive treatment to reduce imported malaria among refugees from east Africa resettling in the United StatesThe effect of dose on the antimalarial efficacy of artemether-lumefantrine: a systematic review and pooled analysis of individual patient data.
P2860
Q17485687-77495BC8-B5AC-4E31-BD7C-A4E9262E13F0Q21034131-6050C48C-36F7-4978-B0F3-E1FA5AE571D6Q21034141-40783F1C-F699-422A-8923-AE52785FCC8CQ22061790-D92A4921-D320-477B-91A9-F664A825B499Q24810617-6D5A4948-DD87-46F5-B1ED-2A9B2AFAEF04Q24814579-3C27571E-0288-4E3B-B8F1-D257512C6C09Q26783646-FD6CB9A2-FB8A-40DC-9F12-C9BBA04429F1Q26783902-8773AB36-0D56-47B7-91C1-325AF1999575Q26830528-7D374337-E3CD-40E0-AB71-F8B2F4AA8885Q28079877-91F854DB-327D-4BAA-89ED-5C950F18678CQ28365926-0999AF2A-5447-4D5B-971C-8E2C0898CFE3Q28472222-731045E8-E235-4C54-A4C8-C8B904383BD7Q28474447-6B399342-829B-4A12-8EB2-CB9EC341FF26Q28489120-9ABCEB4C-4F39-4636-973A-039EC2B871EAQ28547444-5FA982C0-25CD-421D-BA38-6A9CFD21B8B6Q33552774-8032F3A7-211B-452C-B3CB-243B319E11C2Q33559051-44168996-C58E-46F8-B055-63B39AB2ED80Q33601837-1C0AD3B2-2195-4B8D-94B3-C2C4D83C639BQ33635019-BE724D3F-3A08-47C3-8BDB-500409640D73Q33733033-A5A2EE9F-0ED9-4EC0-9DF4-ACF3E70A9767Q33749688-3949BF8B-64F4-4D77-8E2B-C769975E11B3Q33928184-E6728149-7497-4F3E-A08E-431BA12461F1Q33929311-C12DA72B-1C3E-4A74-B434-0972597663F4Q33979153-AE3DF7F5-DCBC-4E92-B721-0CBA76B8220FQ34058351-489FFC02-F9EA-405B-B79B-69B00B73D04EQ34154423-64E35C9B-E4D6-47E8-B9F5-F5B20B9C4E31Q34221884-6CFF6500-D75B-41C5-8517-DFA2FFD58236Q34230161-5A499123-BA0B-4699-A2F0-2ACC3BCBC597Q34267667-65B0598F-71EE-4FDF-91EE-05A55795FFAAQ34281680-E1294127-509F-412F-8DF0-FA07ED5B10B1Q34290067-33708860-0863-40FE-AC65-BAC217A781F2Q34503553-8618365D-9295-4F2C-9741-0488C40FD8DAQ34728230-08C42EB9-4C5B-4E51-AD22-5F0E014F0504Q34983307-1F436FA4-2FB9-467D-BA8D-B441B1755373Q35112348-DF270E39-EF0C-46AE-A808-D18AA33A8F65Q35186742-8BE32ABA-3C81-4F55-9C5F-F7E400814CAAQ35191426-312D1BF5-40E6-4BC1-AC83-8286D948541EQ35203883-EF010C52-81D9-4A60-B209-91277D6DAF42Q35245941-84A9886C-B612-488C-86AA-0D67CF573203Q35580908-41B1E67A-808E-4291-BCB7-9B87D8BF065A
P2860
Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Clinical pharmacokinetics and ...... cs of artemether-lumefantrine.
@ast
Clinical pharmacokinetics and ...... cs of artemether-lumefantrine.
@en
type
label
Clinical pharmacokinetics and ...... cs of artemether-lumefantrine.
@ast
Clinical pharmacokinetics and ...... cs of artemether-lumefantrine.
@en
prefLabel
Clinical pharmacokinetics and ...... cs of artemether-lumefantrine.
@ast
Clinical pharmacokinetics and ...... cs of artemether-lumefantrine.
@en
P1476
Clinical pharmacokinetics and ...... cs of artemether-lumefantrine.
@en
P2093
P304
P356
10.2165/00003088-199937020-00002
P577
1999-08-01T00:00:00Z
P6179
1026118603